Added to YB: 2026-09-03
Pitch date: 2026-08-31
BSLN.SW [neutral]
Basilea Pharmaceutica AG
+3.3%
current return
Author Info
Contrarian Cashflows publishes a monthly deep dive on a new value stock. Sign up for the newsletter.
Company Info
Basilea Pharmaceutica AG is a Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections.
Market Cap
CHF 787.6M
Pitch Price
CHF 63.60
Price Target
108.00 (+64%)
Dividend
N/A
EV/EBITDA
11.08
P/E
15.84
EV/Sales
2.82
Sector
Biotechnology
Category
N/A
Monday Delight: 31/08/2026 - Basilea Pharmaceutica AG
BSLN.SW (monitor): Basilea’s royalty-based anti-infectives model has delivered annual profitability since FY2022, while grants largely fund its two-Phase-3 pipeline expansion. However, the quality appears priced in: a conservative three-year case returns only ~1.7x, versus roughly 40% downside to a hard NAV floor. Watch first Cresemba’s unresolved patent litigation and second olorofim’s race against Basilea’s candidate in invasive mold infections.
Read full article (1 min)